Detection of Minimal Residual Disease and Its Clinical Applications in Melanoma and Breast Cancer Patients.

Publication Title

Advances in experimental medicine and biology

Authors

Selena Y Lin, Department of Translational Molecular Medicine, John Wayne Cancer Institute, Santa Monica, CA, USAFollow
Javier I J Orozco, Department of Translational Molecular Medicine, John Wayne Cancer Institute, Santa Monica, CA, USAFollow
Dave S B Hoon, Department of Translational Molecular Medicine, John Wayne Cancer Institute, Santa Monica, CA, USAFollow

Document Type

Article

Publication Date

1-1-2018

Keywords

Biomarkers; Breast cancer; CTCs; DTCs; Liquid biopsy; MRD; Melanoma; Micrometastases; cfDNA; cfmiR

Abstract

Melanoma and breast cancer (BC) patients face a high risk of recurrence and disease progression after curative surgery and/or therapeutic treatment. Monitoring for minimal residual disease (MRD) during a disease-free follow-up period would greatly improve patient outcomes through earlier detection of relapse or treatment resistance. However, MRD monitoring in solid tumors such as melanoma and BC are not well established. Here, we discuss the clinical applications of MRD monitoring in melanoma and BC patients and highlight the current approaches for detecting MRD in these solid tumors.

Area of Special Interest

Cancer

Area of Special Interest

Women & Children

Specialty/Research Institute

Oncology